Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
24/11/2025 13:11
Nov 24 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA: ENLIVEX ANNOUNCES POSITIVE 6-MONTH TOPLINE DATA –DEMONSTRATING DURABLE AND PERSISTENT PAIN REDUCTION AND IMPROVED FUNCTION IN PRIMARY AGE-RELATED PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS ENLIVEX THERAPEUTICS LTD - TO INITIATE PHASE IIB TRIAL FOR ALLOCETRA IN 2026 Source text: ID:nGNXc9hHYD Further company coverage: ENLV.TA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment